A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

Completed · Phase 2 · Has a placebo group

Conditions studied: Plaque Psoriasis

In brief

Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.

Key facts

Study ID: NCT05223868
Run by: Janssen Research & Development, LLC
People needed: 255
Starts: 2022-02-03
Expected to finish: 2022-12-15
Last updated by the study team: 2026-02-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Participant has a diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 6 months prior to the first administration of study intervention
Participant be a candidate for phototherapy or systemic treatment for plaque psoriasis
Participant has a total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
Participant has a total Psoriasis area and severity index (PASI) >=12 at screening and baseline
Participant has a total Investigator global assessment (IGA) >=3 at screening and baseline

You may not qualify if…

Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
Participant has current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
Participant have previously received any other therapeutic agent directly targeted to interleukin 23 receptor (IL-23R) (including but not limited to guselkumab, tildrakizumab, or risankizumab)
Participant has received any therapeutic agent directly targeted to interleukin 17 receptor (IL-17) or interleukin 12/23 receptor (IL-12/23) (including but not limited to secukinumab, ixekizumab, brodalumab, or ustekinumab) or has received anti-tumor necrosis factor [TNF]-alpha biologic therapy (including, but not limited to adalimumab) within 12 weeks or 5 half-lives, whichever is longer, of the first administration of study intervention
Participant has received agents that deplete B cells (including, but not limited to, rituximab, or alemtuzumab) within 26 weeks of the first administration of study intervention

Where it is running

Pacific Skin Institute — Sacramento, California, United States
Renstar Medical Research — Ocala, Florida, United States
Forcare Clinical Research Inc — Tampa, Florida, United States
Atlanta Dermatology, Vein & Research Center — Alpharetta, Georgia, United States
Arlington Dermatology — Rolling Meadows, Illinois, United States
Dawes Fretzin Clinical Research Group LLC — Indianapolis, Indiana, United States
Indiana Clinical Trial Center — Plainfield, Indiana, United States
DermAssociates, PC — Rockville, Maryland, United States
Hamzavi Dermatology — Fort Gratiot, Michigan, United States
Vivida Dermatology — Las Vegas, Nevada, United States
Windsor Dermatology, PC — East Windsor, New Jersey, United States
Oregon Dermatology and Research Center — Portland, Oregon, United States
University of Pittsburgh Department of Dermatology — Pittsburgh, Pennsylvania, United States
Modern Research Associates — Dallas, Texas, United States
Center for Clinical Studies — Houston, Texas, United States
Austin Institute for Clinical Research — Pflugerville, Texas, United States
Center for Clinical Studies — Webster, Texas, United States
Virginia Clinical Research — Norfolk, Virginia, United States
Dermatology Associates — Seattle, Washington, United States
Premier Clinical Research — Spokane, Washington, United States
Dermatrials Research — Hamilton, Ontario, Canada
Alliance Clinical Trials — Waterloo, Ontario, Canada
XLR8 Medical Research — Windsor, Ontario, Canada
Innovaderm Research — Montreal, Quebec, Canada
Medical Dermatology Specialists — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.